Cynata Therapeutics Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
CYP
- Investments
-
3
- Share Price
-
$0.15
- (As of Friday Closing)
Cynata Therapeutics General Information
Description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Contact Information
Website
www.cynata.comCorporate Office
- Level 3, 100 Cubitt Street
- Cremorne, Victoria 3121
- Australia
Corporate Office
- Level 3, 100 Cubitt Street
- Cremorne, Victoria 3121
- Australia
Cynata Therapeutics Timeline
Cynata Therapeutics Stock Performance
As of 08-Nov-2024, Cynata Therapeutics’s stock price is $0.15. Its current market cap is $26.5M with 181M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.15 | $0.14 | $0.07 - $0.23 | $26.5M | 181M | 85K |
Cynata Therapeutics Financials Summary
As of 30-Sep-2024, Cynata Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
---|---|---|---|---|
EV | 19,266 | 27,633 | 4,161 | 19,111 |
EBITDA | (9,647) | (3,790) | ||
Net Income | (9,598) | (3,946) | ||
Total Assets | 12,573 | 18,263 | ||
Total Debt | 0 | 0 |
Cynata Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Cynata Therapeutics Comparisons
Industry
Financing
Details
Cynata Therapeutics Competitors (5)
One of Cynata Therapeutics’s 5 competitors is Cambium Bio, a Corporate Backed or Acquired company based in Paddington, Australia.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cambium Bio | Corporate Backed or Acquired | Paddington, Australia | ||||
Mesoblast | Corporation | Melbourne, Australia | ||||
Athersys | Formerly VC-backed | Cleveland, OH | ||||
Syntara | Formerly VC-backed | Frenchs Forest, Australia | ||||
Pluri | Corporation | Haifa, Israel |
Cynata Therapeutics Patents
Cynata Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2019900659-A0 | Method | Inactive | 28-Feb-2019 | ||
US-20220119773-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Pending | 28-Feb-2019 | ||
AU-2020227617-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Pending | 28-Feb-2019 | ||
CA-3131395-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Pending | 28-Feb-2019 | ||
EP-3931308-A1 | Method for improving angiogenic potential of a mesenchymal stem cell | Pending | 28-Feb-2019 | C12N5/0691 |
Cynata Therapeutics Signals
Cynata Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Cynata Therapeutics Investments & Acquisitions (3)
Cynata Therapeutics’s most recent deal was a Merger/Acquisition with Cynata. The deal was made on 01-Dec-2013.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Cynata | 01-Dec-2013 | Merger/Acquisition | Drug Discovery | ||
Eco Quest | 25-Oct-2013 | Merger/Acquisition | Biotechnology | ||
Cynata | 17-Sep-2012 | Corporate | Drug Discovery |
Cynata Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Cynata Therapeutics FAQs
-
When was Cynata Therapeutics founded?
Cynata Therapeutics was founded in 2003.
-
Where is Cynata Therapeutics headquartered?
Cynata Therapeutics is headquartered in Cremorne, Australia.
-
What is the size of Cynata Therapeutics?
Cynata Therapeutics has 2 total employees.
-
What industry is Cynata Therapeutics in?
Cynata Therapeutics’s primary industry is Biotechnology.
-
Is Cynata Therapeutics a private or public company?
Cynata Therapeutics is a Public company.
-
What is Cynata Therapeutics’s stock symbol?
The ticker symbol for Cynata Therapeutics is CYP.
-
What is the current stock price of Cynata Therapeutics?
As of 08-Nov-2024 the stock price of Cynata Therapeutics is $0.15.
-
What is the current market cap of Cynata Therapeutics?
The current market capitalization of Cynata Therapeutics is $26.5M.
-
Who are Cynata Therapeutics’s competitors?
Cambium Bio, Mesoblast, Athersys, Syntara, and Pluri are competitors of Cynata Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »